Compare FARM & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FARM | SABS |
|---|---|---|
| Founded | 1912 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.3M | 31.2M |
| IPO Year | N/A | N/A |
| Metric | FARM | SABS |
|---|---|---|
| Price | $1.52 | $4.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $2.75 | ★ $9.00 |
| AVG Volume (30 Days) | 77.3K | ★ 227.8K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $338,816,000.00 | $114,698.00 |
| Revenue This Year | $5.27 | N/A |
| Revenue Next Year | $3.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.34 | $1.00 |
| 52 Week High | $3.29 | $6.60 |
| Indicator | FARM | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 43.16 | 63.81 |
| Support Level | $1.49 | $3.58 |
| Resistance Level | $1.62 | $4.19 |
| Average True Range (ATR) | 0.07 | 0.29 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 40.00 | 78.12 |
Farmer Bros Co is engaged in manufacturing, wholesaling, and distributing coffee, tea, and culinary products to food-service establishments and retailers in the United States. The company's customers include restaurants, hotels, offices, casinos, convenience stores, healthcare facilities, and other food-service providers. The company's product categories include roast and ground coffee, frozen liquid coffee, flavored and unflavored iced and hot teas, culinary products, spices, and other beverages, such as cappuccino, cocoa, granitas, and ready-to-drink iced coffee.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.